Payment overview · 2025
General Payments
$887.29
36 reported records · 17 companies
Healthcare provider profile · identity verified
Shailesh Rajguru, DO
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WINTER HAVEN, FL · NPI 1336192046
Verified facts
What the public records show
CMS Open Payments records show Shailesh Rajguru, DO received $887.29 in general payments during 2025 across 36 reported records.
EMD Serono, Inc. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $182.24 | 20.5% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $177.61 | 20.0% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $126.81 | 14.3% | 6 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $90.85 | 10.2% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $70.56 | 8.0% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $26.96 | 3.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.61 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.79 | 2.5% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $21.10 | 2.4% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $20.63 | 2.3% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$20.19 | 2.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.88 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.48 | 2.1% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $17.84 | 2.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $17.63 | 2.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $16.60 | 1.9% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $15.51 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $887.29 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $197.37 | 9 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $177.61 | 5 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $95.25 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $51.42 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $39.43 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $15.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
113 | 26 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
113 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 760 | 191 |
| Rivastigmine | Rivastigmine Tartrate | 268 | 60 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 234 | 64 |
| Galantamine Er | Galantamine Hbr | 213 | 53 |
| Topiramate | Topiramate | 189 | 44 |
| Levetiracetam | Levetiracetam | 126 | 31 |
| Donepezil Hcl | Donepezil Hcl | 114 | 37 |
| Rexulti | Brexpiprazole | 113 | 26 |
| Lamotrigine | Lamotrigine | 88 | 20 |
| Primidone | Primidone | 79 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 71 | 22 |
| Gabapentin | Gabapentin | 69 | 20 |
| Galantamine Hbr | Galantamine Hbr | 69 | 22 |
| Memantine Hcl Er | Memantine Hcl | 46 | 15 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 28 | suppressed |
| Lacosamide | Lacosamide | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 19 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 18 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 17 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Teriflunomide | Teriflunomide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $887.29 · 36 records | EMD Serono, Inc. | CREXONT, Gamunex-C, Gocovri, INBRIJA, INFINITY, INGREZZA, KISUNLA, Leqembi, Mavenclad, Ocrevus Zunovo, PRECIVITYAD2, REXULTI, VYVGART, VYVGART HYTRULO, WAINUA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error